Role of aspirin in metabolic associated fatty liver disease
- VernacularTitle:阿司匹林在代谢相关脂肪性肝病中的作用
- Author:
Yongqi LI
1
;
Yanqiu LI
1
;
Lina SUN
1
;
Chaoran WANG
1
;
Ying FENG
1
;
Liang WANG
2
;
Xianbo WANG
1
Author Information
- Publication Type:Review
- Keywords: Metabolic Associated Fatty Liver Disease; Aspirin; Drug Therapy
- From: Journal of Clinical Hepatology 2026;42(1):178-182
- CountryChina
- Language:Chinese
- Abstract: Metabolic associated fatty liver disease （MAFLD） is the main type of chronic liver disease in the world， with an increasingly higher incidence rate and a younger age of onset. At present， the treatment of MAFLD mainly depends on lifestyle intervention and comorbidity management， and there is still a lack of effective drugs for MAFLD itself. As a classic nonsteroidal anti-inflammatory drug of the salicylic acid family， aspirin can intervene in the pathological process of MAFLD by regulating lipid metabolism， relieving insulin resistance， reducing liver inflammation and oxidative stress response， exerting an anti-liver fibrosis effect， and inhibiting hepatocellular carcinoma， and therefore， it has the value of preventing disease onset， delaying disease progression， and reversing disease condition. This article systematically reviews the mechanism of action and safety of aspirin in the treatment of MAFLD， in order to provide more drug treatment options for MAFLD patients.
